Neurogene Inc. - Common Stock (NQ:NGNE)

26.47 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurogene Inc. - Common Stock

< Previous 1 2 3 4 Next >

Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

November 12, 2025

From Neurogene Inc.

Via Business Wire

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

November 06, 2025

From Neurogene Inc.

Via Business Wire

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 05, 2025

From Neurogene Inc.

Via Business Wire

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗

November 04, 2025

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 09, 2025

Via Benzinga

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

October 09, 2025

From Neurogene Inc.

Via Business Wire

Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

October 08, 2025

From Neurogene Inc.

Via Business Wire

4 Biotech Stocks Seeing Explosive Momentum Gains ↗

October 07, 2025

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be...

Via Benzinga

Topics ETFs Stocks

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025

From Neurogene Inc.

Via Business Wire

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 05, 2025

From Neurogene Inc.

Via Business Wire

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗

September 04, 2025

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.

Via Benzinga

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

August 11, 2025

From Neurogene Inc.

Via Business Wire

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction ↗

August 11, 2025

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.

Via Benzinga

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 08, 2025

From Neurogene Inc.

Via Business Wire

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗

July 30, 2025

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 11, 2025

Via Benzinga

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 03, 2025

From Neurogene Inc.

Via Business Wire

Which stocks are moving on Tuesday? ↗

July 01, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 01, 2025

Via Benzinga

Which stocks are experiencing notable movement on Tuesday? ↗

July 01, 2025

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

June 30, 2025

From Neurogene Inc.

Via Business Wire

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2025

From Neurogene Inc.

Via Business Wire

This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday ↗

May 16, 2025

Via Benzinga

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

May 16, 2025

From Neurogene Inc.

Via Business Wire

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 14, 2025

Via Benzinga

Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

May 13, 2025

Via Benzinga

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

May 09, 2025

From Neurogene Inc.

Via Business Wire

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 08, 2025

From Neurogene Inc.

Via Business Wire

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

April 28, 2025

From Neurogene Inc.

Via Business Wire

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

April 02, 2025

From Neurogene Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.